Pharmacology of moxonidine: An I1-imidazoline receptor agonist

Journal of Cardiovascular Pharmacology

Volumn 35, Issue SUPPL. 4, 2000, Pages

  Ernsberger, P ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Imidazoline receptor; Moxonidine; PC12 pheochromocytoma cells; Radioligand binding; Rats

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPINE; ALPHA 2 ADRENERGIC RECEPTOR; ARACHIDONIC ACID; CIMETIDINE; CIRAZOLINE; CLONIDINE; CORBADRINE; EFAROXAN; GUANABENZ; GUANFACINE; IDAZOXAN; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I1 RECEPTOR AGONIST; MEDETOMIDINE; MOXONIDINE; NEUROTRANSMITTER RECEPTOR; PHOSPHOLIPID; PIPEROXAN; RAUWOLSCINE; RILMENIDINE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTORS;

BRAIN STEM; DRUG BINDING SITE; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; KIDNEY; MEDULLA OBLONGATA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE CELL; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; HYPERTENSION; METABOLISM; NERVE CELL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; IMIDAZOLES; NEURONS; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG;

EID: 0033652267     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200000004-00005     Document Type: Review

References (162)

1. 1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease
2. 2-adrenergic receptors in the rostral ventrolateral medulla
3. 2-adrenoceptors in the ventrolateral medulla
4. Nonadrenergic imidazoline binding sites on human platelets
5. 2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes
6. 1-Imidazoline receptors: Definition, characterization, distribution and transmembrane signalling
7. Astrocytes cultured from specific brain regions differ in their expression of adrenergic binding sites
8. 2-imidazoline binding sites on monoamine oxidases
9. The imidazoline preferring receptor: Binding studies in bovine, rat and human brainstem
10. 2-adrenoceptors and imidazoline binding sites: Distribution of imidazoline binding sites in rat brain
11. Imidazole receptors and blood pressure regulation. High receptor selectivity of moxonidine
12. Imidazoline binding sites on PC12 cells and bovine chromaffin cells
13. Nonadrenergic imidazoline binding sites on human platelets
14. 1-imidazoline sites
15. 2-adrenoceptors in rat brain membranes
16. 2 adrenoceptors
17. Central hypotensive effects of the α(2a)-adrenergic receptor subtype
18. 1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells
19. 2-adrenergic receptor subtypes in a cell type-specific manner
20. 1-imidazoline receptors
21. Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits
22. 2+ in human erythroleukemia cells
23. α(2A)-Adrenoceptors mediate activation of non-selective cation channels via G(i)-proteins in human erythroleukaemia (HEL) cells. No evidence for a functional role of imidazoline receptors in modulating calcium
24. Effects of clonidine and other imidazole-receptor binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells
25. Effect of clonidine on second messenger systems in rat adrenal gland
26. 1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla
27. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla
28. 1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells
29. 1-imidazoline receptors in the rostral ventrolateral medulla
30. Effect of the imidazoline receptor ligand moxonidine on human platelet aggregation
31. Effects of moxonidine, an imidazoline antihypertensive agent, on second messenger systems in rat brain
32. 2-adrenergic and imidazoline receptors in brain
33. Effects of imidazolines on noradrenaline release in brain: An investigation into their relationship to imidazoline, alpha 2 and H3 receptors
34. Localization of the central cardiovascular action of clonidine
35. 2-adrenoceptor blockade by SKF-86466: In vitro characterization of receptor selectivity
36. 1-imidazoline receptor agonist
37. 1-imidazoline receptor activation on responses of hypoglossal and phrenic nerve to chemical stimulation
38. Ocular actions of moxonidine: A possible role for imidazoline receptors
39. The central effects of moxonidine on intraocular pressure and its antagonism by L-659, 066 and L-657, 743 in the rabbit
40. 1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease
41. 1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla
42. 2-adrenoceptor involvement in the central cardiovascular action of clonidine in the conscious renal hypertensive cat
43. The interaction between prazosin and clonidine at α-adrenoceptors in rats and cats
44. Reversal of clonidine-induced hypotension by α-adrenoceptor blocking drugs
45. 2-adrenoceptors in the cardiovascular effects of moxonidine
46. Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha(2A)-adrenoceptor transgenic mice
47. 2-Adrenergic receptors are not required for central antihypertensive action of moxonidine in mice
48. 2-adrenoceptors affect sleep and arousal mechanisms
49. Selectivity of rilmenidine for the nucleus reticularis lateralis, a ventrolateral medullary structure containing imidazoline-preferring receptors
50. 1-Imidazoline receptors mediate arachidonic acid release from PC12 pheochromocytoma cells
51. No evidence for functional imidazoline receptors on locus coeruleus neurons
52. Characterization of α-adrenergic receptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthine
53. Synergistic behavioral interaction between ethanol and clonidine in rats: Role of alpha-2 adrenoceptors
54. Modulation of catecholamine release by alpha 2-adrenoceptors and I1-imidazoline receptors in rat brain
55. Crossover comparison of moxonidine and clonidine in mild to moderate hypertension
56. A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects
57. Hypertension: A possible risk in road traffic
58. General pharmacology of the novel centrally acting antihypertensive agent moxonidine
59. Drug withdrawal and rebound hypertension: Differential action of the central antihypertensive drugs moxonidine and clonidine
60. Aspects of tolerability of centrally acting antihypertensive drugs
61. Therapeutic applications of agents interacting with α-adrenoceptors
62. Centrally acting antihypertensive agents: A comparison of lofexidine with clonidine
63. 2-adrenergic blocker
64. Inhibition of respiratory neural discharges by clonidine and 5-hydroxytryptophan
65. Haemodynamic effects of a new centrally acting antihypertensive agent moxonidine as compared to clonidine
66. 2-agonists, guanfacine and clonidine, in regard to duration of antinociception, and ventilatory and hemodynamic effects in goats
67. 2-adrenergic receptors in the carotid body response to isocapnic hypoxia
68. Imidazoline receptors and human brain disorders
69. Imidazoline receptor antisera-selected cDNA clone and mRNA distribution
70. Characterization of a partial cDNA clone detected by imidazoline receptor-selective antisera
71. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system
72. Alpha(2)-adrenoceptors and I-1-imidazoline binding sites: Relationship with catecholamines in women of reproductive age
73. 2-adrenergic receptors: Implications for depression
74. 1-imidazoline receptors in mood disorders
75. 2-autoreceptors are involved in the blood pressure-lowering effect of moxonidine
76. Differential patterns of local cerebral glucose utilisation associated with rilmenidine- or B-HT 933-induced hypotension
77. Regulation of phenylethanolamine N-methyltransferase gene expression by imidazoline receptors in adrenal chromaffin cells
78. 1-imidazoline sites in bovine adrenal medullary membranes
79. Nonadrenergic modulation by clonidine of the cosecretion of catecholamines and enkephalins in adrenal chromaffin cells
80. 2-Adrenoceptor blockade prevents cardiac glycoside-evoked neurotransmitter release from sympathetic nerves in dog saphenous vein
81. Novel targets and techniques in imidazoline receptor research
82. 2-imidazoline binding sites to inhibitory effects of imidazolines on ligand-gated ion channels. An investigation in the adrenal medulla and in neuroblastoma cells
83. Rilmenidine (S 3341) and the sympathoadrenal system: Adrenoreceptors, plasma and adrenal catecholamines in dogs
84. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent
85. Influence of imidazolines on catecholamine release in pithed spontaneously hypertensive rats
86. 1-imidazoline receptors: Binding, visualization and modulatory function
87. Characterization and visualization of clonidine-sensitive imidazole sites in rat kidney which recognize clonidine-displacing substance
88. Peripheral and central imidazoline receptor-mediated natriuresis in the rat
89. Inhibition of the natriuretic action of the imidazoline receptor agonist moxonidine by indometacin in the rat
90. The sympathetic nervous system and the kidney: Its importance in renal diseases
91. Rilmenidine: A novel antihypertensive agent
92. Effect of rilmenidine on arterial pressure and urinary output in the spontaneously hypertensive rat
93. 1) receptors and renal mechanisms in relation to their antihypertensive therapeutic potential
94. Identification, localization and functional analysis of imidazoline and α-adrenergic receptors in canine prostate
95. Characteristics of the binding of the antihypertensive agent moxonidine to α2-adrenoceptors in rat brain membranes
96. Imidazoline receptor antisera-selected cDNA clone and mRNA distribution
97. Signal transduction by nerve growth factor and fibroblast growth factor in PC12 cells requires a sequence of Src and Ras actions
98. 1 receptor agonist, moxonidine, inhibits insulin secretion from isolated rat islets of Langerhans
99. Induction of defective insulin secretion and impaired glucose tolerance by clonidine: Selective stimulation of metabolic α-adrenergic pathways
100. Clonidine and ST-91 may activate imidazoline binding sites in the heart to release atrial natriuretic peptide
101. Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: Comparison to clonidine and GHRH
102. Psychopharmacology of imidazoline and α2-adrenergic receptors: Implications for depression
103. Effects of clonidine and yohimbine on parasympathetic reflex salivation and vasodilatation in cat SMG
104. 1-imidazoline receptors and cholinergic outflow to the airways
105. Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients
106. 3H]clonidine binding sites in rat stomach: High affinity of imidazolines, guanidines and sigma ligands
107. Moxonidine decreases gastric secretion and gastric mucosal injury in rats
108. Influence of clonidine and a new related imidazoline derivative (tizanidine) on rat gastric mucosa
109. Efaroxan acts peripherally to block the antisecretory and gastroprotective effects of moxonidine in rats
110. Agmatine, the bacterial amine, is widely distributed in mammalian tissues
111. General pharmacology of the novel centrally acting antihypertensive agent moxonidine
112. Influence of different dietary salts on the cardiovascular and renal effects of moxonidine in spontaneously hypertensive rats
113. 1-imidazoline agonist
114. 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats
115. Moxonidine: A second-generation central antihypertensive agent
116. Myocardial infarction accompanying acute clonidine withdrawal in a patient without a history of ischemic coronary artery disease
117. Precipitation by yohimbine of the withdrawal syndromes of clonidine, guanfacine, and methyldopa in the spontaneously hypertensive rat
118. Distinctive features of rilmenidine possibly related to its selectivity for imidazoline receptors
119. Effects of continuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine (S 3341) on cardiovascular and behavioral parameters of spontaneously hypertensive rats
120. 2-noradrenergic receptors mediate feeding induced by paraventricular nucleus injection of norepinephrine and clonidine
121. Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central symaptholytic agent
122. 1-agonist moxonidine, elicit food intake in spontaneously hypertensive rats (SHR)
123. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB)
124. 1 binding site in rat brown adipocytes
125. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla
126. Imidazoline receptors: A new concept in central regulation of the arterial blood pressure
127. 1-imidazoline receptors
128. 1-imidazoline receptors
129. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol
130. Imidazoline receptor agonist drugs: A new approach to the treatment of systemic hypertension
131. Imidazoline receptors: From basic concepts to recent developments
132. Clinical pharmacology of imidazolines and related compounds
133. Rilmenidine and vigilance: Review of clinical studies
134. Cardiovascular and central nervous system effects of rilmenidine (S 3341) in rats
135. 2-adrenoceptor agonist rilmendine
136. Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function
137. Long-term control of blood pressure by rilmenidine in high-risk populations
138. Rilmenidine: A new novel approach to first-line treatment
139. The use of moxonidine in the treatment of hypertension
140. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla (RVLM)
141. The effects of rilmenidine on tests of autonomic function in humans
142. Comparison of moxonidine and clonidine HCl in treating patients with hypertension
143. Comparison between the effects of ST 600 and catapres
144. The use of moxonidine in the treatment of hypertension
145. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: Moxonidine versus captopril
146. 1-imidazoline-receptor agonists in the treatment of hypertension: An appraisal of clinical experience
147. Rilmenidine in mild to moderate essential hypertension: A double-blind, randomized, parallel-group, multicenter comparison with methyldopa in 157 patients
148. Comparative effects of rilmenidine and clonidine on bronchial responses to histamine in asthmatic subjects
149. Functional and autoradiographic studies to locate the sites at which clonidine acts to cause hyperglycaemia and inhibition of opiate-induced sympathetic outflow
150. 2-adrenoceptor agonists
151. The central hyperglycemic effect of clonidine
152. 2-adrenoceptors in glucoregulation
153. Functional and autoradiographic studies to locate the sites at which clonidine acts to cause hyperglycaemia and inhibition of opiate-induced sympathetic outflow
154. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat
155. Why imidazoline receptor modulator in the treatment of hypertension?
156. 1 imidazoline preferring receptors: Two unique sites mediating natriuresis in the rat
157. 2-receptors in the uterus, heart and gastric mucosa
158. 2-receptors in rat cerebral cortex
159. 2 receptors by clonidine
160. Investigations into the positive inotropic effect of clondine in isolated hearts
161. Effective antihypertensive therapy: Blood pressure control with moxonidine
162. Clinical pharmacology of imidazolines and related compounds